HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Chemical differentiating agents. Differentiation of HL-60 cells by hexamethylenebis[acetamide] analogues.

Abstract
Hexamethylenebis[acetamide] (HMBA) is an agent in clinical trial that induces differentiation of certain types of tumor cells to nonmalignant phenotypes. In an attempt to discover a more potent compound, a number of bis-functionalized amides, imides, and hydrazine derivatives of HMBA were prepared and evaluated in vitro with the HL-60 human promyelocytic leukemia cell line. Among the compounds evaluated, the 5,5-dimethylhydantoin derivative is almost 10 times more potent than HMBA in inducing differentiation. The bis-imide, diacetyl-HMBA, is both more potent and effective than its parent compound. Six of the 16 compounds evaluated cause at least 20% differentiation. An inverse relationship between the degree of differentiation and the percentage of viable cells is described for HMBA and its analogues.
AuthorsA Haces, T R Breitman, J S Driscoll
JournalJournal of medicinal chemistry (J Med Chem) Vol. 30 Issue 2 Pg. 405-9 (Feb 1987) ISSN: 0022-2623 [Print] United States
PMID3806621 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Acetamides
  • Indicators and Reagents
  • hexamethylene bisacetamide
Topics
  • Acetamides (chemical synthesis, pharmacology)
  • Cell Differentiation (drug effects)
  • Cell Line
  • Humans
  • Indicators and Reagents
  • Magnetic Resonance Spectroscopy
  • Mass Spectrometry
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: